CONNECT WITH US
AI & Deeptech

AI & Deeptech

Swiss AI drug trial startup receives funding from Spotify-backer Creandum

IndiaTimes (ET) - AI logo

Published on

Add as a preferred source on Google
Swiss AI drug trial startup receives funding from Spotify-backer Creandum

Business News Tech AI Swiss AI drug trial startup receives funding from Spotify-backer Creandum

An AI foundation model, trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said.

ZURICH: Swiss AI start-up Atlast Bio , which runs drug trials on virtual patients , has received $12.5 million in funding led by Swedish venture capital firm Creandum , an early backer of Spotify and Trade Republic, the company said on Tuesday. * Atlas Bio is aiming to replace Phase II drug trials, which it says cost more than $100 million, take two to three years and see about 70% of drugs fail at that stage * An AI foundation model , trained on about two million human RNA readouts, would replace these and animal testing with 12-week simulations, the company said

* Virtual trials can also evaluate drugs across multiple diseases simultaneously, something not feasible in conventional clinical trials, Atlas Bio added * Results from a first trial are expected within 6 weeks * Atlas Bio was founded by former Google employees alongside AI and pharmaceutical specialists

Atlast Bio Creandum AI drug trials drug development virtual patients funding for biotech atlas bio AI foundation model

(Catch all the Technology News News , and Latest News Updates on The Economic Times .)

Elevate your knowledge and leadership skills at a cost cheaper than your daily tea.

KYC and KYB: Inside Damani’s Avenue Supermarts that refuses to charge more – Part 1 of 3


Source link
Related Topics:AI & Deeptech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.